Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 How to Use this Report

6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Angiogenesis Drug Targets

• 7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer

8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Anti-Angiogenic Drugs

10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets

11 Available Biological Structure Data on Anti-Angiogenic Drug Targets

12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology

• 12.1.1 Carboxy-Lyase Activity
• 12.1.2 Catalytic Activity
• 12.1.3 Cell Adhesion Molecule Activity
• 12.1.4 Chaperone Activity
• 12.1.5 Cofactor Binding
• 12.1.6 Cysteine-Type Peptidase Activity
• 12.1.7 Cytokine Activity
• 12.1.8 DNA Topoisomerase Activity
• 12.1.9 DNA-Directed DNA Polymerase Activity
• 12.1.10 Extracellular Matrix Structural Constituent
• 12.1.11 G-Protein Coupled Receptor Activity
• 12.1.12 Growth Factor Activity
• 12.1.13 GTPase Activity
• 12.1.14 Hydrolase Activity
• 12.1.15 Kinase Activity
• 12.1.16 Lipid Kinase Activity
• 12.1.17 Metallopeptidase Activity
• 12.1.18 Molecular Function Unknown
• 12.1.19 Motor Activity
• 12.1.20 Peptidase Activity
• 12.1.21 Protease Inhibitor Activity
• 12.1.22 Protein Serine/Threonine Kinase Activity
• 12.1.23 Protein-Tyrosine Kinase Activity
• 12.1.24 Receptor Activity
• 12.1.25 Receptor Binding
• 12.1.26 Serine-Type Peptidase Activity
• 12.1.27 Structural Constituent of Cytoskeleton
• 12.1.28 Superoxide Dismutase Activity
• 12.1.29 Transcription Factor Activity
• 12.1.30 Transcription Regulator Activity
• 12.1.31 Translation Regulator Activity
• 12.1.32 Transmembrane Receptor Activity
• 12.1.33 Transmembrane Receptor Protein Tyrosine Kinase Activity
• 12.1.34 Transporter Activity

13 The Drug-Protein Interactome of Anti-Angiogenic Drugs

14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations

• 14.1 Target Profiles of Anti-Angiogenic Drugs on the Market
• 14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
• 14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
• 14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
• 14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical Development
• 14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target Combinations

15 Anti-Angiogenic Drug Target Mix by Cancer Indication

• 15.1 Adrenal Cancer
• 15.2 Biliary Cancer
• 15.3 Bladder Cancer
• 15.4 Bone Cancer
• 15.5 Brain Cancer
• 15.6 Breast Cancer
• 15.7 Carcinoid Tumor
• 15.8 Cervical Cancer
• 15.9 Chemotherapy-Induced Infection
• 15.10 Colorectal Cancer
• 15.11 Endometrial Cancer
• 15.12 Fallopian Tube Cancer
• 15.13 Gastrointestinal Cancer
  • 15.13.1 Gastrointestinal Stomach Cancer
  • 15.13.2 Gastrointestinal Stromal Cancer
• 15.14 Head and Neck Cancer
• 15.15 Leukemia
  • 15.15.1 Acute Lymphocytic Leukemia
  • 15.15.2 Acute Myelogenous Leukemia
  • 15.15.3 Chronic Lymphocytic Leukemia
  • 15.15.4 Chronic Myelogenous Leukemia
• 15.16 Liver Cancer
• 15.17 Lung Cancer
  • 15.17.1 Non-Small Cell Lung Cancer
  • 15.17.2 Small Cell Lung Cancer
• 15.18 Lymphoma
  • 15.18.1 B-Cell Lymphoma
  • 15.18.2 Hodgkin' s Lymphoma
  • 15.18.3 Non-Hodgkin' s Lymphoma
• 15.19 Melanoma
• 15.20 Mesothelioma
• 15.21 Myelodysplastic Syndrome
• 15.22 Myeloma
• 15.23 Nasopharyngeal Cancer
• 15.24 Oesophageal Cancer
• 15.25 Ovarian Cancer
• 15.26 Pancreatic Cancer
• 15.27 Peritoneal Cancer
• 15.28 Prostate Cancer
• 15.29 Renal Cancer
• 15.30 Sarcoma
  • 15.30.1 Leiomyo Sarcoma
• 15.31 Squamous Cell Cancer
• 15.32 Thyroid Cancer

16 Anti-Angiogenic Drugs and Their Targets by Companies

• 16.1 Australia
• 16.2 Austria
• 16.3 Belgium
• 16.4 Canada
• 16.5 China
• 16.6 Denmark
• 16.7 France
• 16.8 Germany
• 16.9 Israel
• 16.10 Japan
• 16.11 Netherlands
• 16.12 South Korea
• 16.13 Spain
• 16.14 Sweden
• 16.15 Switzerland
• 16.16 United Kingdom
• 16.17 USA

17 Disclaimer

18 Drug Index

19 Company Index

List of Figures

• Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs
• Figure 2: Primary Sub-cellular Localization of Drug Targets
• Figure 3: Visualization of Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
• Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs
• Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic Drugs

List of Tables

• Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
• Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug Targets
• Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug Targets
• Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways
• Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
• Table 10: Number of Available Biological Structures on Anti-Angiogenic Drug Targets
• Table 11: Overview of Drug Target Profile Themes
• Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome
• Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
• Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market
• Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
• Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
• Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
• Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical Development
• Table 19: The Progression, Maturity and Comptitive Comparison of Anti-Angiogenic Drug Target Mixes in Development
• Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by Cancer Indication
• Table 21: The Competitive Situation on Bevacizumab (Avastin)
• Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
• Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
• Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
• Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
• Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
• Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
• Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug
• Table 30: Anti-angiogenic Drug Target Mix for the Treatment of Chemotherapy-induced Infection According to the Compound Type and Developmental Stage of Drug
• Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
• Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
• Table 34: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Cancer (General) According to the Compound Type and Developmental Stage of Drug
• Table 35: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
• Table 36: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
• Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Drug
• Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
• Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
• Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
• Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Drug
• Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Drug
• Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 50: Anti-angiogenic Drug Target Mix for the Treatment of Non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
• Table 52: Anti-angiogenic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
• Table 53: Anti-angiogenic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
• Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
• Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
• Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
• Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
• Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma (General) According to the Compound Type and Developmental Stage of Drug
• Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
• Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
• Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Australia
• Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Austria
• Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Belgium
• Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Canada
• Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in China
• Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Denmark
• Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in France
• Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Germany
• Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Israel
• Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Japan
• Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in the Netherlands
• Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Sweden
• Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Switzerland
• Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in United Kingdom
• Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in USA